Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge

PURPOSE: Pegaspargase (PEG-ASP) has largely replaced native Escherichia coli asparaginase (L-ASP) in the treatment of acute lymphoblastic leukemia because of its longer half-life and lower immunogenicity. Risk factors for allergic reactions to PEG-ASP remain unclear. Here, we identify risk factors f...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Liu, Yiwei, Smith, Colton A., Panetta, John C., Yang, Wenjian, Thompson, Lauren E., Counts, Jacob P., Molinelli, Alejandro R., Pei, Deqing, Kornegay, Nancy M., Crews, Kristine R., Swanson, Hope, Cheng, Cheng, Karol, Seth E., Evans, William E., Inaba, Hiroto, Pui, Ching-Hon, Jeha, Sima, Relling, Mary V.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2019
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6804844/
https://ncbi.nlm.nih.gov/pubmed/31188727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.02439
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky